825 related articles for article (PubMed ID: 14992195)
41. High-dose chemotherapy for peripheral stem cell procurement in leukemia, lymphoma and multiple myeloma.
Rugo HS; Damon LE; Ries CA; Wolf JL; Linker CA
Prog Clin Biol Res; 1994; 389():505-11. PubMed ID: 7535460
[No Abstract] [Full Text] [Related]
42. Graft clonogenicity and intensity of pre-treatment: factors affecting outcome of autologous peripheral hematopoietic cell transplantation in patients with acute myeloid leukemia in first remission.
Strodtbeck D; Bornhäuser M; Hänel M; Lerche L; Schaich M; Illmer T; Thiede C; Geissler G; Herbst R; Ehninger G; Platzbecker U
Bone Marrow Transplant; 2005 Dec; 36(12):1083-8. PubMed ID: 16247435
[TBL] [Abstract][Full Text] [Related]
43. Autologous stem cell transplantation in myelodysplastic syndromes.
de Witte T; Suciu S; Brand R; Muus P; Kröger N
Semin Hematol; 2007 Oct; 44(4):274-7. PubMed ID: 17961727
[TBL] [Abstract][Full Text] [Related]
44. Prospective randomized comparative observation of single- versus split-dose lenograstim to enhance engraftment after autologous stem cell transplantation in patients with multiple myeloma or non-Hodgkin's lymphoma.
Jang G; Ko OB; Kim S; Lee DH; Huh J; Suh C
Transfusion; 2008 Apr; 48(4):640-6. PubMed ID: 18194384
[TBL] [Abstract][Full Text] [Related]
45. Is our current strategy in manipulating hemopoiesis in autologous transplantation correct?
To LB
Stem Cells; 1993 Jul; 11(4):283-9. PubMed ID: 8104615
[TBL] [Abstract][Full Text] [Related]
46. [Cellular therapy for intensification in oncology and hematology: manipulation of peripheral blood stem-cell products].
Douay L
Bull Cancer; 2001 Sep; 88(9):826-32. PubMed ID: 11604353
[TBL] [Abstract][Full Text] [Related]
47. Hematopoietic stem cell transplantation in multiple myeloma.
Pant S; Copelan EA
Biol Blood Marrow Transplant; 2007 Aug; 13(8):877-85. PubMed ID: 17640590
[TBL] [Abstract][Full Text] [Related]
48. High-dose chemotherapy and autologous transplant with peripheral-blood stem cells.
Vose JM; Armitage JO; Kessinger A
Oncology (Williston Park); 1993 Aug; 7(8):23-9; discussion 29-30, 33-4. PubMed ID: 8104456
[TBL] [Abstract][Full Text] [Related]
49. Nonmyeloablative stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia in patients 60 years or older.
Gupta V; Daly A; Lipton JH; Hasegawa W; Chun K; Kamel-Reid S; Tsang R; Yi QL; Minden M; Messner H; Kiss T
Biol Blood Marrow Transplant; 2005 Oct; 11(10):764-72. PubMed ID: 16182177
[TBL] [Abstract][Full Text] [Related]
50. A single dose of 6 or 12 mg of pegfilgrastim for peripheral blood progenitor cell mobilization results in similar yields of CD34+ progenitors in patients with multiple myeloma.
Bruns I; Steidl U; Kronenwett R; Fenk R; Graef T; Rohr UP; Neumann F; Fischer J; Scheid C; Hübel K; Haas R; Kobbe G
Transfusion; 2006 Feb; 46(2):180-5. PubMed ID: 16441592
[TBL] [Abstract][Full Text] [Related]
51. Risk assessment in haemotopoietic stem cell transplantation: disease and disease stage.
Chaidos A; Kanfer E; Apperley JF
Best Pract Res Clin Haematol; 2007 Jun; 20(2):125-54. PubMed ID: 17448953
[TBL] [Abstract][Full Text] [Related]
52. [Hematopoietic stem cell transplantation in multiple myeloma].
Vela-Ojeda J; Ruiz-Esparza MA
Rev Invest Clin; 2005; 57(2):305-13. PubMed ID: 16524072
[TBL] [Abstract][Full Text] [Related]
53. Cytoreduction of lymphoid malignancies and mobilization of blood hematopoietic progenitor cells with high doses of cyclophosphamide and etoposide plus filgrastim.
Damon L; Rugo H; Tolaney S; Navarro W; Martin T; Ries C; Case D; Ault K; Linker C
Biol Blood Marrow Transplant; 2006 Mar; 12(3):316-24. PubMed ID: 16503501
[TBL] [Abstract][Full Text] [Related]
54. Blood and marrow transplantation activity in Europe 1996. European Group for Blood and Marrow Transplantation (EBMT).
Gratwohl A; Passweg J; Baldomero H; Hermans J
Bone Marrow Transplant; 1998 Aug; 22(3):227-40. PubMed ID: 9720735
[TBL] [Abstract][Full Text] [Related]
55. Autologous peripheral blood progenitor cells cryopreserved with 5 and 10 percent dimethyl sulfoxide alone give comparable hematopoietic reconstitution after transplantation.
Akkök CA; Liseth K; Nesthus I; Løkeland T; Tefre K; Bruserud O; Abrahamsen JF
Transfusion; 2008 May; 48(5):877-83. PubMed ID: 18298599
[TBL] [Abstract][Full Text] [Related]
56. Reduced dose of lenograstim is as efficacious as standard dose of filgrastim for peripheral blood stem cell mobilization and transplantation: a randomized study in patients undergoing autologous peripheral stem cell transplantation.
Ataergin S; Arpaci F; Turan M; Solchaga L; Cetin T; Ozturk M; Ozet A; Komurcu S; Ozturk B
Am J Hematol; 2008 Aug; 83(8):644-8. PubMed ID: 18508321
[TBL] [Abstract][Full Text] [Related]
57. Allogeneic and autologous stem cell transplantation in myelodysplastic syndromes.
De Witte T
Pathol Biol (Paris); 1997 Oct; 45(8):643-9. PubMed ID: 9569930
[TBL] [Abstract][Full Text] [Related]
58. Role of antithymocyte globulin and granulocyte-colony stimulating factor-mobilized bone marrow in allogeneic transplantation for patients with hematologic malignancies.
Chen XH; Zhang C; Zhang X; Gao L; Gao L; Kong PY; Peng XG; Qi DG; Sun AH; Zeng DF; Liu H; Gong Y; Wang QY
Biol Blood Marrow Transplant; 2009 Feb; 15(2):266-73. PubMed ID: 19167687
[TBL] [Abstract][Full Text] [Related]
59. Long-term outcome of myeloablative allogeneic stem cell transplantation for multiple myeloma.
Kuruvilla J; Shepherd JD; Sutherland HJ; Nevill TJ; Nitta J; Le A; Forrest DL; Hogge DE; Lavoie JC; Nantel SH; Toze CL; Smith CA; Barnett MJ; Song KW
Biol Blood Marrow Transplant; 2007 Aug; 13(8):925-31. PubMed ID: 17640596
[TBL] [Abstract][Full Text] [Related]
60. CD34+ cell responsiveness to stromal cell-derived factor-1alpha underlies rate of engraftment after peripheral blood stem cell transplantation.
Marquez-Curtis LA; Turner AR; Larratt LM; Letcher B; Lee SF; Janowska-Wieczorek A
Transfusion; 2009 Jan; 49(1):161-9. PubMed ID: 18954402
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]